
Christian Schem, MD
Advertisement
Articles by Christian Schem, MD



Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer.
Advertisement
Latest Updated Articles
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE TrialPublished: June 23rd 2025 | Updated:
Expanding Role of Ovarian Suppression/ Ablation in Premenopausal ER-Positive Breast Cancer: Issues and OpportunitiesPublished: January 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma
2
How KTX-1001 May Address Gap in Unique Multiple Myeloma Biologic Subtype
3
Joining Commercialization and Innovation to Bring New Cancer Therapies
4
Phase 2b Prostate Cancer Study Receives FDA Clearance in High-Risk Groups
5
